Skip to main content

Table 1 Patients and their classification according to responses based on disease activity score and C-reactive protein level after 12 weeks of infliximab treatment

From: The effects of infliximab therapy on the serum proteome of rheumatoid arthritis patients

Patient ID number DAS28 Δ DAS EULAR DAS28 responsea CRP mg/L Δ CRP
  Baseline (T0) Week 12 (T12)    Baseline (T0) Week 12 (T12)  
10611 5.7 5.2 0.5 NR 4.3 29.1 -24.8
10612 6.2 7.6 -1.4 NR 37.4 139.0 -101.6
10613 5.8 3.6 2.3 R 13.0 9.0 4.0
10616 6.8 3.9 2.9 R 46.0 1.0 45.0
10618 6.3 3.8 2.5 NRb 43.3 52.0 -8.7
10619 3.2 3.7 -0.5 NR 6.0 8.0 -2.0
10620 4.9 5.1 -0.2 NR 17.1 2.3 14.8
10621 3.8 4.2 -0.5 NR 68.0 68.0 0.0
10622 6.0 6.6 -0.6 NR 24.4 86.2 -61.8
10623 6.2 4.5 1.7 R 51.3 12.4 38.9
  1. aPatients were deemed to be European League Against Rheumatism (EULAR) responders (Rs) if they had a reduction in DAS28 of greater than or equal to 1.2; all others were considered non-responders (NRs) for analysis purposes. bSubject 10618 achieved a reduction in DAS28 of 2.5, but C-reactive protein (CRP) level increased at T12; thus, to ensure homogeneity in the R group, we excluded this patient from the group. DAS, disease activity score; DAS28, disease activity score using 28 joint counts.